CD8A and neoplasm: - OV-mOX40L inhibited tumor growth in vivo- Local treatment of OV-mOX40L stimulated intratumoral immune cells.- OV-mOX40L activated CD4+ T cells and CD8+ cytotoxic T cells and reduced Treg proportion leading to switching the TME to a more pro-inflammatory state.